Drug intelligence / Profile preview

bacille Calmette-Guerin vaccine

Development stage
Unknown
Lead developer
Sant'Andrea Hospital
Modality
Vaccines & Immunotherapeutics
Administration
Intradermal
01

Overview

Bacille Calmette-Guérin (BCG) vaccine is a live attenuated strain of *Mycobacterium bovis* traditionally used for tuberculosis prevention. In a clinical program led by S. Andrea Hospital, it is being repurposed as an immunomodulatory therapy for radiologically isolated syndrome (RIS), a preclinical stage of multiple sclerosis. The vaccine is administered as a single intradermal injection and is hypothesized to prevent neuroinflammation and the progression of demyelinating lesions by inducing tumor necrosis factor (TNF) and modulating systemic immune responses. This approach aims to provide a safe, cost-effective, and accessible secondary prevention strategy for individuals at high risk of developing clinical multiple sclerosis.

Brand names
TICE BCGOncoTICEImmucystBCG Vaccine
Other names
BCGBacillus Calmette-GuerinBCG vaccineBCG Moreau
02

Targets

αMβ2 (Integrin αMβ2)CD209 (Dendritic cell-specific intercellular adhesion Molecule-3-Grabbing non-integrin)CLEC4E (Macrophage-inducible C-type lectin receptor)MRC1 (Mannose Receptor C-type 1)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on bacille Calmette-Guerin vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bacille Calmette-Guerin vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call